{
  "id": "64178f94690f196b51000027",
  "type": "summary",
  "question": "What is eteplirsen's mechanism of action?",
  "ideal_answer": "Eteplirsen is an antisense oligonucleotide that binds to exon 51 of the dystrophin gene, resulting in exon skipping and the production of a truncated but functional dystrophin protein.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30171554",
    "http://www.ncbi.nlm.nih.gov/pubmed/27807823",
    "http://www.ncbi.nlm.nih.gov/pubmed/29339778",
    "http://www.ncbi.nlm.nih.gov/pubmed/22086232",
    "http://www.ncbi.nlm.nih.gov/pubmed/29278896",
    "http://www.ncbi.nlm.nih.gov/pubmed/34797383",
    "http://www.ncbi.nlm.nih.gov/pubmed/28865998",
    "http://www.ncbi.nlm.nih.gov/pubmed/28280301"
  ],
  "snippets": [
    {
      "text": "exon-skipping therapy including eteplirsen (brand name Exondys 51), a synthetic antisense oligonucleotide designed to skip exon 51 of the dystrophin gene",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34797383",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "a phosphorodiamidate morpholino oligomer (PMO) antisense oligonucleotide eteplirsen received accelerated approval by the US Food and Drug Administration (FDA) in 2016. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34797383",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Eteplirsen (Exondys\u00a051) is an antisense oligonucleotide designed to induce exon 51 skipping that is developed by Sarepta Therapeutics.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807823",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In September 2016, the US Food and Drug Administration granted accelerated approval for eteplirsen (or Exondys 51), a drug that acts to promote dystrophin production by restoring the translational reading frame of DMD through specific skipping of exon 51 in defective gene variants.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28280301",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, eteplirsen, a phosphorodiamidate morpholino oligomer-based splice-switching oligonucleotide (SSO) targeting DMD exon 51, was approved by the U.S. Food and Drug Administration as the first antisense-based drug for DMD patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29339778",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The FDA conditionally approved the first exon-skipping AON, called eteplirsen (brand name ExonDys51), targeting exon 51 of the DMD gene, in late 2016.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30171554",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In 2016, the US Food and Drug Administration (FDA) conditionally approved the first phosphorodiamidate morpholino oligomer (morpholino)-based AO drug, eteplirsen, developed for DMD exon 51 skipping.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28865998",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Currently, there is no cure, though exon-skipping therapy including eteplirsen (brand name Exondys 51), a synthetic antisense oligonucleotide designed to skip exon 51 of the dystrophin gene, is considered especially promising.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34797383",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "in protein. Eteplirsen, a phosphorodiamidate morpholino oligomer (PMO), is designed to skip exon 51, restore the reading frame, and induce production of internally shortened dystrophin in patients with mutations amenable to such treatment.OBJECTIVE: Describe lung function assessed throughout eteplirsen studies 201/202.METHODS: Studies 201/202 included 12 patients treat",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29278896",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We previously conducted a proof of principle; dose escalation study in Duchenne muscular dystrophy (DMD) patients using the morpholino splice-switching oligonucleotide AVI-4658 (eteplirsen) that induces skipping of dystrophin exon 51 in patients with relevant deletions, restores the open reading frame and induces dystrophin protein expression after intramuscular (i.m.)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086232",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}